{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+control&page=3",
    "query": {
      "intervention": "Reference control",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 371,
    "total_pages": 38,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+control&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+control&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T04:24:46.640Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02160587",
      "title": "Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Surgical Site Infection"
      ],
      "interventions": [
        {
          "name": "Chloraprep",
          "type": "DRUG"
        },
        {
          "name": "0.9% Physiological Saline",
          "type": "DRUG"
        },
        {
          "name": "ZuraPrep without IPA",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Zurex Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 208,
      "start_date": "2014-07",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-03-17",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 1,
      "location_summary": "Bozeman, Montana",
      "locations": [
        {
          "city": "Bozeman",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02160587"
    },
    {
      "nct_id": "NCT05565729",
      "title": "A Phase I Study of LY3471851 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3471851",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Levocetirizine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 41,
      "start_date": "2022-10-05",
      "completion_date": "2023-02-23",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05565729"
    },
    {
      "nct_id": "NCT00518115",
      "title": "Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Albiglutide (GSK716155) or exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 361,
      "start_date": "2007-04",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2016-12-16",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 158,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bull Shoals",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00518115"
    },
    {
      "nct_id": "NCT00451451",
      "title": "Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BG00012",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Glatiramer Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1417,
      "start_date": "2007-06",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00451451"
    },
    {
      "nct_id": "NCT02924857",
      "title": "The Chocolate Touch Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Peripheral Artery Disease (PAD)",
        "Ischemia",
        "Intermittent Claudication"
      ],
      "interventions": [
        {
          "name": "Chocolate Touch",
          "type": "DEVICE"
        },
        {
          "name": "Lutonix Drug Coated Balloon",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "TriReme Medical, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 333,
      "start_date": "2017-07-26",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 15,
      "location_summary": "Gainesville, Florida • Miami Beach, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Houma",
          "state": "Louisiana"
        },
        {
          "city": "Dearborn",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924857"
    },
    {
      "nct_id": "NCT07623837",
      "title": "Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Ocular Motility Disorders",
        "Strabismus",
        "Extraocular Muscle Dysfunction",
        "Thyroid Eye Disease"
      ],
      "interventions": [
        {
          "name": "Glandy EOM (AI-based quantitative eye movement analysis software)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "THYROSCOPE INC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2026-07-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 1,
      "location_summary": "San Jose, California",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07623837"
    },
    {
      "nct_id": "NCT04305353",
      "title": "Intensive Care Unit (ICU) Diary Project",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "PTSD",
        "Post ICU Syndrome"
      ],
      "interventions": [
        {
          "name": "Diary (blank journal) plus PTSD psycho-education",
          "type": "OTHER"
        },
        {
          "name": "PTSD psycho-education alone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Tulane University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-09-26",
      "completion_date": "2020-09-01",
      "has_results": false,
      "last_update_posted_date": "2021-04-13",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04305353"
    },
    {
      "nct_id": "NCT05077969",
      "title": "Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "2019 Novel Coronavirus Disease",
        "2019 Novel Coronavirus Infection",
        "2019-nCoV Disease",
        "2019-nCoV Infection",
        "COVID-19",
        "COVID-19 Pandemic",
        "COVID-19 Virus Disease",
        "COVID-19 Virus Infection",
        "Covid19",
        "Coronavirus Disease 2019",
        "SARS-CoV2 Infection",
        "SARS-CoV-2 Acute Respiratory Disease"
      ],
      "interventions": [
        {
          "name": "Famotidine",
          "type": "DRUG"
        },
        {
          "name": "Celecoxib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leidos Life Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-12-29",
      "completion_date": "2022-07-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 15,
      "location_summary": "Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Hazlehurst",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05077969"
    },
    {
      "nct_id": "NCT07805044",
      "title": "Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "PHYSIOLOGICAL PHENOMENA",
        "Homeostasis",
        "Physical Functional Performance",
        "Cardiorespiratory Fitness",
        "Cardiometabolic Risk Factors",
        "Mobility Limitation"
      ],
      "interventions": [
        {
          "name": "Standardized Physiologic Resilience Challenge",
          "type": "PROCEDURE"
        },
        {
          "name": "Multimodal Whole-Body Physiologic Monitoring",
          "type": "OTHER"
        },
        {
          "name": "Research-Only Whole-Body Digital Twin Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Truway Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 450,
      "start_date": "2026-08-31",
      "completion_date": "2041-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07805044"
    },
    {
      "nct_id": "NCT07795567",
      "title": "A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Ivermectin Cream 1%",
          "type": "DRUG"
        },
        {
          "name": "Soolantra™ Cream 1%",
          "type": "DRUG"
        },
        {
          "name": "PrRosiver® Cream 1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 865,
      "start_date": "2025-12-09",
      "completion_date": "2026-06-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-18T04:24:46.640Z",
      "location_count": 1,
      "location_summary": "Hawthorne, New York",
      "locations": [
        {
          "city": "Hawthorne",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07795567"
    }
  ]
}